► Home ﹥Research and Development ﹥ PEGylaltion Technology Platform


In the field of protein drug design, the process of pegylation of the therapeutic protein preserves its biological activity by targeting the PEG polymer (polyethylene glycol) at a specific and defined region on the protein. PharmaEssentia's pegylation technology platform is designed to increase the protein drug's efficacy by prolonging its circulation in the bloodstream. Utilizing its innovative 40K PEG and its novel pegylation technology platform by combining protein engineering and PEG-related chemistry, PharmaEssentia creates novel products for better disease treatment. Compared with the similar drugs on the market, the long-acting protein drugs produced by the technology possess the most effective PK/PD data as well as reduced side effects, as these PEG-proteins are designed as predominantly single forms without other isomers which may induce severe side effects. 

PharmaEssentia's novel pegylation technology platform has yielded our lead product, ropeginterferon alfa-2b, which is currently being explored in several indications. Ropeginterferon alfa-2b is a novel engineered interferon alpha 2b, designed to be the most purer interferon alpha designed. Other interferon alphas on the market currently include PEG-Intron (Merck) and Pegasys (Roche). Our ropeginterferon alfa-2b offers the following advantages:

  The predominantly single-site-specific conjugation pegylation, resulting in a >90% single isomer composition.
  Much higher MTD than Pegasys and PEG-Intron, resulting in a dosing of one injection every 2 weeks vs. Pegasys and PEG-Introns’ once weekly injections.
 
  As a result of our pure composition, we have seen evidence of improved side effect profile while maintaining the same efficacy as other pegylated interferons in earlier stage trials in PV as well as in Hepatitis C.
 



Copyright © 2008 PharmaEssentia Corporation All Rights Reserved.